APRINOIA Therapeutics ^{Withdrawn, Nasdaq: APRI}

We are a clinical-stage biotechnology company committed to protecting patients’ brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. We are developing three platforms to diagnose and treat these disorders, namely: (1) positron emission tomography (“PET”) diagnostic tracers for tau and a-Syn aggregates, with 18F-APN-1607 (INN: florzolotau) (“APN-1607”) being a 3 carboxy-terminal (“3R”)/4 carboxy-terminal domains (“4R”) tau PET tracer for the diagnosis of PSP and related disorders, as well as AD; (2) an antibody platform, with APNmAb005 being a novel monoclonal antibody designed to offer greater selectivity for pathologic forms of tau that contribute to the pathogenesis of AD and primary tauopathies; and (3) a protein degrader platform based on the proteolysis targeting chimeras (“PROTAC”) that targets pathological a-Syn and tau proteins, which we believe potentially represents one of the more innovative therapeutic approaches for the treatment of neurodegenerative diseases, an area previously thought to be undruggable by traditional small molecules.